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INTRODUCTION 
 
 
Main aim of haematuria evaluation in patients is to diagnose Urothelia 
cancer. The incidence of urothelial cancer in patients with haematuria is 6 to 
12 %. Most of the urothelial cancer are from the bladder, upper tract tumor 
incidence is only 0.5 %. 
Patients with haematuria can be of two types 
1. Visible haematuria otherwise known as gross haematuria 
2. Microscopic haematuria. Defined as more than 3 RBCs per high power 
field 
Patients with gross haematuria have higher incidence of (30 percent) 
urothelial cancer. 
Currently recommended investigations for haematuria evaluation are 
1.  CT of the abdomen and pelvis (As it is more superior to IVU and 
Ultrasound in detecting lesions) 
2.  Urine cytology for malignant cells and 
3. Cystoscopy 
Boback et al in his study made a cost estimation for haematuria 
evaluation and the sensitivity of the investigations done. The highlights of the 
study is presented below : 
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The study by Boback et al has shown that the cost of evaluation of 
haematuria is around 1000 dollars, which is a significant amount to be spent on 
each patient. Main bulk of the cost is due to the CT imaging and cystoscopy. 
CT evaluation cannot be avoided as it is essential for detecting lesions other 
than the urothelial tumors like stone disease and renal cell carcinoma. 
So attention was focused on alternative methods other than cystoscopy 
to rule out bladder tumors which will cut down the cost of evaluation 
dramatically. 
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Currently cystoscopy is the ‘gold standard’ to rule out that the patient is 
not having a bladder lesion to account for the haematuria. Because it can be 
seen  in the above table from the study by Boback et al CT (62 %) and cytology 
(27 %) are not as sensitive as Cystoscopy. 
This led the search of cost effective but highly sensitive modalities 
which are as sensitive as cystoscopy . This has resulted in two modalities in the 
horizon: 
1. Molecular markers in urine 
2. Virtual cystoscopy 
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Similar to cystoscopy virtual evaluation of the upper tracts can also be 
done to rule out urothelial tumors named as virtual ureteroscopy and virtual 
nephroscopy. Collectively virtual cystoscopy, ureteroscopy and nephroscopy 
are called as Virtual endoscopy 
Virtual endoscopy (VE) is a 3D computer rendering technique with the 
possibility of interactive intraluminal navigation within the bladder simulating 
a conventional endoscopy 
VE is possible with the routine CT images which we do for patients with 
haematuria when the software is available so there is no added cost to the 
patient. 
Virtual imaging is possible by the Marching cubes algorithm which is 
used to delineate the mucosa. It is based on the change in the attenuation values 
between the fluid (contrast filled urine) in the bladder lumen and the bladder 
wall. This results in a 3D representation of the  mucosal surface. The computer 
mouse can be moved within the lumen as if we move the endoscope within the 
bladder and ureter and the entire mucosa examined systematically in an 
interactive manner. 
(Lorensen WE, Clic HE. Marching cubes:a high resolution 3D surface 
construction algorithm. Comput Graph 1987; 21:163 – 9) 
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AIM AND OBJECTIVE 
 
 
To compare virtual endoscopy (VE) and Trans-abdominal ultrasound 
with Conventional cystoscopy (CC), in the detection of bladder tumors in 
patients with haematuria. 
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REVIEW OF LITERATURE 
 
 
To visualize the renal pelvis and ureter the delayed CECT images are 
sufficient. But to visualize the bladder is a bit difficult. 
To apply the marching cubes algorithm there must be a good attenuation 
gradient between the bladder lumen and the mucosa.Based on the virtual 
endoscopic examination of the para nasal sinuses and tracheobronchial tree 
where the air in the passages offered good attenuation gradient initial virtual 
cystoscopic examination was based on carbondioxide insufflation of bladder. 
Filling the bladder with gas also allows good attenuation gradient 
between the lumen and the mucosa. Even virtual colonoscopy is possible by 
insufflating carbon di oxide in the colon. 
So Virtual cystoscopy had been initially attempted by filling bladder 
with 300 ml of carbon dioxide by Vining et al and also by others like Noriasu 
et al, the problem is the bladder continuously forms urine and urine stays in the 
bladder base and carbon di oxide floating above. As urine doesn’t offer good 
attenuation gradient the lesions in the bladder base were missed. For these 
reasons contrast cystogram is superior for virtual endoscopic evaluation of 
bladder. 
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To ensure a good attenuation gradient between the lumen and mucosa 
diluted contrast must be present in the bladder. To achieve this catheter was 
introduced in the bladder and urine drained followed by contrast instillation 
into the bladder as done by Roberto iglesias et al. 
Or an infant feeding tube can also be used for contrast instillation as 
done by Kishore et al. The smaller caliber of the infant feeding tube produces 
little discomfort than a catheter. 
But still these are invasive methods as it is similar to introducing a small 
size flexible cystoscope and are not truly non - invasive. 
Merkle et al Showed that it is feasible to create VC after an intravenous 
injection with contrast media. 
Similar VC studies using intra venous contrast was done by 
Thiagarajan nambirajan et al. 
So we did not insert catheter into the bladder as it itself is invasive. We 
waited for 30 minutes for the contrast to fill the bladder. During the waiting 
period we made the patient ambulant so that there is no gravitation of the 
contrast and ensured mixing of contrast well with urine. Those patients on a 
stretcher were moved to right and left lateral positions repeatedly. Screening 
cystogram was done to make sure that a dense homogenous cystogram was 
present before 64 slice bladder imaging. 
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The original multislice CT devices had four rows of detectors, but recent 
multislice CT devices which are produced by several manufacturers, comprise 
a single rotating X-ray tube that provides a beam of photons travelling through 
the patient, and which are then received by multiple rows of detectors, thus 
effectively producing multiple slices for each rotation of the X-ray tube. These 
multislice CT devices produce more refined three dimensional images, and are 
increasingly used in coronary angiography and virtual endoscopy. 
Noriyasu Kawai et al have used 16 slice CT for VC Intravenous 
urography-virtual cystoscopy is a better preliminary examination than air 
virtual cystoscopy 
We have used 64 slice CT in our study which we thought will improve 
the diagnostic ability 
If CT-based VC has enough sensitivity, this combined with CT 
urography could potentially be a single, noninvasive screening investigation for 
haematuria. This could replace the current use of combined cystoscopy (CC) 
and upper tract assessment with CT urogram . 
We assessed the feasibility and efficacy of CT based VC and compared 
it with conventional cystoscopy (CC), using intravenous contrast media, 
thereby avoiding catheterization and 64 slice CT to enhance sensitivity 
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HAEMATURIA EVALUATION 
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Blood in the urine (haematuria) can originate from any site along the 
urinary tract and, whether gross or microscopic, may be sign of serious 
underlying disease, including malignancy. Overall the incidence of urothelial 
cancer in patients with haematuria is around 6 – 12 %.  The literature agrees 
that gross haematuria warrants a thorough diagnostic evaluation as the 
incidence of urothelial cancer is high ( 30 % ). In microscopic hematuria the 
incidence reported is variable .Mayo clinic reports on analyzing 2000 patients 
that only 0.5 % had a urologic malignancy and 1.8 % developed other serious 
urologic diseases within 3 years after identification of of haematuria ( Mohr et 
al, 1986 ) .Conversely investigators at the University of Wisconsin found that 
26 % of adults who had at least one positive dipstick reading for haematuria 
were subsequently found to have significant urologic pathology ( Messing et al , 
1987 ). This variation may be due to the presence of patients of varying risk for 
disease in the study groups. So patients were classified into high risk and low 
risk groups to further evaluate microscopic haematuria. High risk patients with 
microscopic haematuria have an urothelial cancer risk of 30 %and hence a 
complete work up is indicated. Whereas only limited work up is indicated in 
low risk patients. And another issue is whether physicians should test for 
haematuria in asymptomatic patients remains at issue. No major organization 
currently recommends screening for microscopic hematuria in asymptomatic 
adults. 
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The initial determination of microscopic hematuria should be based on 
microscopic examination of urinary sediment from a freshly voided, clean-
catch, midstream urine specimen. Hematuria can be measured quantitatively by 
any of the following: 
(1)  Determination of the number of red blood cells per milliliter of 
urine excreted (chamber count) 
(2)  Direct examination of the centrifuged urinary sediment (sediment 
count) 
(3)  Indirect examination of the urine by dipstick (the simplest way to 
detect microscopic haematuria). 
Given the limited specificity of the dipstick method (65 percent to 99 
percent for two to five red blood cells per high-power microscopic field), 
however the sensitivity is over 90 % , the initial finding of microscopic 
haematuria by the dipstick method should be confirmed by microscopic 
evaluation of urinary sediment. 
The recommended definition of microscopic hematuria is three or more 
red blood cells per high-power field on microscopic evaluation of urinary 
sediment from two of three properly collected urinalysis specimens. To account 
for intermittent positive tests for haematuria in patients with urologic 
malignancies, one group of investigators proposed that patients with more than 
three red blood cells per high-power field from two of three properly collected 
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urine specimens should be considered to have microhaematuria and, thus, 
should be evaluated appropriately. However, before a decision is made to defer 
evaluation in patients with one or two red blood cells per high-power field, risk 
factors for significant disease should be taken into consideration. High-risk 
patients should be considered for full urologic evaluation after one properly 
performed urinalysis documenting the presence of at least three red blood cells 
per high-power field. 
Risk Factors for Significant Disease in Patients with Microscopic 
Hematuria 
1.  Smoking history 
2.  Occupational exposure to chemicals or dyes (benzenes or aromatic 
amines) 
3.  History of gross hematuria 
4.  Age >40 years 
5.  History of urologic disorder or disease 
6.  History of irritative voiding symptoms 
7.  History of urinary tract infection 
8.  Analgesic abuse 
9. History of pelvic irradiation 
The prevalence of microscopic haematuria varies from 0.19 percent to as 
high as 21 percent. In five population-based studies, the prevalence of 
asymptomatic microscopic haematuria varied from 0.19 percent to 16.1 percent. 
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Differences in the age and sex of the populations screened, the amount of 
follow-up and the number of screening studies per patient account for this 
range. In older men, who are at a higher risk for significant urologic disease, 
the prevalence of microscopic haematuria was as high as 21 percent. 
Patients with microscopic haematuria who are at risk for urologic 
disease or primary renal disease should undergo an appropriate evaluation. In 
patients at low risk for disease, some components of the evaluation may be 
deferred. An algorithm for the initial evaluation of newly diagnosed 
microscopic haematuria is provided below. 
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An approach to the urologic evaluation of patients without conditions 
suggestive of primary renal disease is presented in the algorithm below. 
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The presence of significant proteinuria, red cell casts or renal 
insufficiency or a predominance of dysmorphic red blood cells in the urine 
should prompt an evaluation for renal parenchymal disease or referral to a 
nephrologist. Significant proteinuria is defined as a total protein excretion of 
greater than 1,000 mg per 24 hours (1 g per day), or greater than 500 mg per 24 
hours (0.5 g per day) if protein excretion is persistent or increasing or if other 
factors suggest the presence of renal parenchymal disease. In the absence of 
massive bleeding, a total protein excretion in excess of 1,000 mg per 24 hours 
would be unlikely and should prompt a thorough evaluation or nephrology 
referral. Red cell casts are virtually pathognomonic for glomerular bleeding. 
Unfortunately, they are a relatively insensitive marker. Therefore, it is useful to 
examine the character of the red blood cells.25 Dysmorphic urinary red blood 
cells show variation in size and shape and usually have an irregular or distorted 
outline. Such red blood cells are generally glomerular in origin. In contrast, 
normal doughnut shaped red blood cells are generally due to lower urinary tract 
bleeding. Accurate determination of red blood cell morphology may require 
inverted phase contrast microscopy. 
The percentage of dysmorphic red blood cells required to classify 
haematuria as glomerular in origin has not been adequately defined. In general, 
glomerular bleeding is associated with more than 80 percent dysmorphic red 
blood cells, and lower urinary tract bleeding is associated with more than 80 
percent normal red blood cells. Percentages falling between these ranges are 
indeterminate and could represent bleeding from either source. 
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The initial evaluation of the urinary sediment generally identifies 
patients with parenchymal renal disease.4 Glomerular disease is most likely in 
this setting and may be associated with a variety of systemic diseases, 
including lupus erythematosus, vasculitis, malignancy and infections such as 
hepatitis and endocarditis. Glomerular diseases localized to the kidney include 
membranoproliferative glomerulonephritis, IgA nephropathy and crescentic 
glomerulonephritis. In addition, interstitial renal disease, such as drug induced 
interstitial disease or analgesic nephropathy, may be associated with 
haematuria. If systemic causes are not identified, renal biopsy is usually 
recommended. 
Patients with microscopic haematuria, a negative initial urologic 
evaluation and no evidence of glomerular bleeding are considered to have 
isolated hematuria. Although many such patients may have structural 
glomerular abnormalities, they appear to have low risk for progressive renal 
disease. Thus, the role of renal biopsy in this setting has not been defined. 
Nevertheless, because follow-up data are limited, these patients should be 
followed for the development of hypertension, renal insufficiency or 
proteinuria. In patients without risk factors for primary renal disease, a 
complete urologic evaluation should be performed. Complete urologic 
evaluation of microscopic hematuria includes a history and physical 
examination, laboratory analysis and radiologic imaging of the upper urinary 
tract followed by cystoscopic examination of the urinary bladder. In some 
instances, cytologic evaluation of exfoliated cells in the voided urine specimen 
may also be performed. If a careful history suggests a potential “benign” cause 
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for microscopic hematuria the patient should undergo repeat urinalysis 48 
hours after cessation of the activity (i.e., menstruation, vigorous exercise, 
sexual activity or trauma). No additional evaluation is warranted if the 
hematuria has resolved. Patients with persistent hematuria require evaluation. 
In women, urethral and vaginal examinations should be performed to 
exclude local causes of microscopic hematuria. A catheterized urinary 
specimen is indicated if a clean catch specimen cannot be reliably obtained  
(i.e., because of vaginal contamination or obesity). In uncircumcised men, the 
foreskin should be retracted to expose the glans penis, if possible. If a phimosis 
is present, a catheterized urinary specimen may be required. The laboratory 
analysis begins with comprehensive examination of the urine and urinary 
sediment. The number of red blood cells per high-power field should be 
determined. In addition, the presence of dysmorphic red blood cells or red cell 
casts should be noted. 
The urine should also be tested for the presence and degree of 
proteinuria and for evidence of urinary tract infection. Patients with urinary 
tract infection should be treated appropriately, and urinalysis should be 
repeated six weeks after treatment. If the hematuria resolves with treatment, no 
additional evaluation is necessary. Serum creatinine should be measured. The 
remaining laboratory investigation should be guided by specific findings of the 
history, physical examination and urinalysis. Urothelial cancers, the target of a 
cytologic examination, are the most commonly detected malignancies in 
patients with microscopic haematuria. 
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Voided urinary cytology is recommended in all patients who have risk 
factors for transitional cell carcinoma.This test can be a useful adjunct to 
cystoscopic evaluation of the bladder, especially in the determination of 
carcinoma in situ. In patients with microscopic haematuria who do not have 
risk factors for transitional cell carcinoma, urinary cytology or cystoscopy may 
be used. If cytology is chosen and malignant or atypical/suspicious cells are 
identified, cystoscopy is required because the presence of haematuria is a 
significant risk factor for malignancy in such patients. 
Several recently identified voided urinary markers have been examined 
for the early detection of bladder cancer. At this time, insufficient data are 
available to recommend their routine use in the evaluation of patients with 
microscopic hematuria. Further studies are warranted to determine the role of 
these markers in the diagnostic evaluation of such patients. Intravenous 
urography, ultrasonography and computed tomography are used to evaluate the 
urinary tract in patients with microscopic hematuria. Because of lack of impact 
data, evidence-based imaging guidelines cannot be formulated. In patients with 
microscopic hematuria, imaging can be used to detect renal cell carcinoma, 
transitional cell carcinoma in the pelvicaliceal system or ureter, urolithiasis and 
renal infection. Table below highlights imaging modalities used to evaluate the 
urinary tract. 
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Intravenous urography (IVU) has traditionally been the modality of 
choice for imaging the urinary tract, and many still consider it to be the best 
initial study for the evaluation of microhematuria. However, IVU by itself has 
limited sensitivity in detecting small renal masses. When a mass is detected by 
IVU, further lesion characterization by ultrasonography, computed tomography 
(CT) or magnetic resonance imaging (MRI) is necessary because IVU cannot 
distinguish solid from cystic masses. CT is the best imaging modality for the 
evaluation of urinary stones, renal and perirenal infections, and associated 
complications. For the detection of transitional cell carcinoma in the kidney or 
ureter, IVU is superior to ultrasonography. CT urography with abdominal 
compression results in reliable opacification of the collecting system, 
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comparable to that obtained with IVU. High detection rates for transitional cell 
carcinoma on contrast-enhanced CT images have been reported, but the studies 
offer no statistical analysis.There are currently no studies  comparing the 
performance of various diagnostic- imaging modalities in the detection of 
transitional cell carcinomas in the upper urinary tract. Retrograde pyelography 
is considered the best imaging approach for the detection and characterization 
of ureteral abnormalities, but this general opinion is not based on evidence. No 
data exist showing the impact of IVU, ultrasonography, CT or MRI on the 
management of patients with microscopic hematuria. Therefore, evidence-
based imaging guidelines cannot be formulated. If CT is chosen as the initial 
upper tract study, the imaging protocol should be adapted to the diagnostic 
goals, such as the exclusion of urolithiasis and renal neoplasm. CT urography 
spiral (helical) is preferred if the technology is available. Neither oral nor rectal 
contrast medium is required. The CT protocols should start with a noncontrast 
scan. If this scan demonstrates urolithiasis in a patient who is at low risk for 
underlying malignancy no further scanning is needed. In all other patients, 
including those in whom a urinary calculus is not detected, intravenous contrast 
medium should be injected. CT scout (topogram) or plain-film abdominal 
radiography (depending on the equipment available) can be performed at the 
end of the CT examination to assess the ureters and bladder in an IVU–like 
fashion. Even better is multiplanar reconstruction of the available source 
images. 
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Cystoscopic evaluation of the bladder (complete visualization of the 
bladder mucosa, urethra and ureteral orifices) is necessary to exclude the 
presence of bladder cancer. 
Cystoscopy as a component of the initial office evaluation of 
microscopic hematuria is recommended in all adult patients more than 40 years 
of age and in patients less than 40 years of age with risk factors for bladder 
cancer. This includes patients in whom upper tract imaging reveals a 
potentially benign source for bleeding. Cystoscopy appears to have a low yield 
in select patients at low risk for bladder cancer, including men and women 
younger than 40 years with no risk factors for this malignancy.In these patients, 
initial cystoscopy may be deferred, but urinary cytology should be performed. 
Initial diagnostic cystoscopy can be performed under local anesthesia using a 
rigid or flexible cystoscope. Compared with rigid cystoscopy, flexible 
cystoscopy causes less pain and is associated with fewer post-procedure 
symptoms.In addition, positioning and preparation of the patient are simplified, 
and procedure time is reduced. Flexible cystoscopy appears to be at least 
equivalent in diagnostic accuracy to rigid cystoscopy; for some lesions  
(i.e., those at the anterior bladder neck), it may be superior. 
Because some patients with a negative initial evaluation for  
microhaematuria eventually develop significant urologic disease, some form of 
follow-up is indicated. Although most patients with a negative initial 
evaluation for microhaematuria do not develop significant urologic disease, 
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some patients do. Consequently, some form of follow-up is indicated. Because 
the appearance of haematuria can precede the diagnosis of bladder cancer by 
many years, such follow-up seems especially important in high- risk groups, 
including patients older than 40 years and those who use tobacco or whose 
occupational exposures put them at risk.Because the risk of life-threatening 
lesions in patients with a negative initial evaluation is low and the data 
regarding follow-up in such patients are sparse, recommendations regarding 
appropriate follow-up must be based on consensus opinion, in addition to 
review of the available literature-based evidence. In patients with a negative 
initial evaluation of asymptomatic microscopic haematuria, consideration 
should be given to repeating urinalysis, voided urine cytology and blood 
pressure determination at six, 12, 24 and 36 months. 
Although cytology may not be a sensitive marker for detecting low-
grade transitional cell carcinoma, it detects most high-grade tumors and 
carcinomas in situ, particularly if the test is repeated. Such high-grade lesions 
are the most likely to benefit from early detection. 
Additional evaluation, including repeat imaging and cystoscopy, may be 
warranted in patients with persistent hematuria in whom there is a high index 
of suspicion for significant underlying disease. In this setting, the clinical 
judgment of the treating physician should guide further evaluation. Immediate 
urologic reevaluation, with consideration of cystoscopy, cytology or repeat 
imaging, should be performed if any of the following occur: (1) gross 
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hematuria, (2) abnormal urinary urinary cytology or (3) irritative voiding 
symptoms in the absence of infection. If none of these occurs within three years, 
the patient does not require further urologic monitoring. Further evaluation for 
renal parenchymal disease or referral to a nephrologist should be considered if 
hematuria persists and hypertension, proteinuria or evidence of glomerular 
bleeding (red cell casts, dysmorphic red blood cells) develops. 
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UROTHELIAL CARCINOMA 
 
Carcinoma in Situ  
Carcinoma in situ may appear as a velvety patch of erythematous  
mucosa, although quite often it  is endoscopically invisible.  
Histologically, it consists of poorly differentiated TCC confined to the  
urothelium .Carcinoma in situ may be asymptomatic or may produce  
severe symptoms of urinary frequency, urgency, and dysuria ( Utz et al ,   
1970 ; Utz and Farrow, 1984 ). Urine cytopathology is positive in 80%  
to 90% of patients with carcinoma in situ. 
Carcinoma in situ is present in 25% or more of patients with  
 
high-grade superficial tumors ( Koss et al,  1974 ), and between 40%  
 
and 83% progress to muscle-invasive cancer ( Althausen et al,  1976 ).  
 
Carcinoma in situ occurs in 20% to 75% of high-grade muscle-invasive  
 
cancers. Patients with marked urinary symptoms generally have a  
 
shorter interval preceding the development of muscle-invasive cancer.  
 
About 20% of patients treated with cystectomy for diffuse carcinoma in  
 
situ are found to have microscopic muscle-invading cancer ( Farrow et  
 
al,  1976 ). 
 
A variety of investigative approaches have confirmed carcinoma  
 
in situ's direct relationship to muscle-invading cancer. Cytogenetic  
 
(loss of chromosome 17p) ( Olumni et al,  1990 ; Tsai et al,  1990 ;  
 
Knowles et al,  1994 ),  molecular genetic ( Sarkis et al,  1993 ),  and  
 
immunohistologic (Sarkis et al,  1993, 1994 [533] [534]; Esrig et al,   
 
1994 ) studies have shown that high proportions of both carcinoma in  
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situ and deeply invasive bladder cancer have deletions and/or  
 
mutations of the TP53 gene and alterations of its protein product. This  
 
not only supports the contention that carcinoma in situ is a precursor  
 
lesion of invasive bladder cancer but also, to a large degree, eliminates  
 
i t  as a precursor of low-grade papillary tumors in which TP53  
 
abnormalities are rarely found (except in extremely young patients)  
 
(  Habuchi et al,  1992 ; Spruck et al,  1994 ; Linn et al,  1998 ). 
 
Transitional Cell (Urothelial) Carcinoma  
 
Tumor Architecture  
 
More than 90% of bladder cancers are TCCs . At a consensus  
 
conference, the pathologists of the WHO and the ISUP preferred to  
 
term these urothelial cancers (Epstein et al,  1998 ); such a name may  
 
be confusing for nonpathologists because cancers of other histologic  
 
types, such as squamous cancers and adenocarcinomas, also arise in the  
 
urothelium. Regardless of name, urothelial (transitional cell) cancers  
 
differ from normal urothelium by having an increased number of  
 
epithelial cell layers with papillary foldings of the mucosa, loss of cell  
 
polarity, abnormal cell maturation from basal to superficial layers,  
 
increased nuclear-cytoplasmic ratio, prominent nucleoli,  clumping of  
 
chromatin, and increased number of mitoses ( Koss, 1975 ).  
 
Urothelial carcinomas demonstrate a variety of patterns of tumor  
 
growth, including papillary, sessile, infiltrating, nodular, mixed, and  
 
flat intraepithelial growth (carcinoma in situ). Cancer invasion between  
 
and through the smooth muscle cells of the tunica muscularis mucosa  
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(within the lamina propria) can be mistaken for invasion of the bladder  
 
detrusor muscle ( Younes et al,  1990 ; Engel et al,  1992 ), a particular  
 
problem in specimens obtained by endoscopic biopsy or transurethral  
 
curettage. 
 
Urothelium has great metaplastic potential; therefore, urothelial  
 
carcinomas may contain spindle cell  (  Young et al,  1988 ),  squamous,  
 
or adenocarcinomatous elements. These elements are present in about  
 
one third of muscle-invasive urothelial bladder cancers, and several  
 
may be exhibited in a single cancer. Approximately 70% of bladder  
 
tumors are papillary, 10% are nodular, and 20% are mixed. 
 
Tumor Grading  
 
No uniformly accepted grading system for bladder cancer exists.   
 
Most commonly used systems are based on the degree of anaplasia of  
 
the tumor cells ( Broders, 1922 ; Bergkvist et al,  1965 ; Mostofi et al,   
 
1973 ; Koss, 1975 ). In a consensus conference, the WHO and the ISUP  
 
decided to classify many of these tumors as papillary urothelial  
 
neoplasms ( Epstein et al,  1998 ). 
 
A strong correlation exists between tumor grade and stage  
 
(Jewett and Strong, 1946 ),  with most well-differentiated and  
 
moderately differentiated tumors being superficial and most poorly  
 
differentiated ones being muscle invasive. Stage for stage, there is a  
 
significant correlation between tumor grade and prognosis; however,  
 
the correlation between tumor stage and prognosis is even stronger. As  
 
several authors ( Knowles et al,  1994 ; Spruck et al,  1994 ; Reznikoff  
 
et al,  1996 ; Cote and Chatterjee, 1999 ) have proposed, there are now  
molecular and cytogenetic data to support the well-established clinical  
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impression that low-grade (all  well-differentiated and most moderately  
 
differentiated) tumors and high-grade (poorly differentiated) tumors  
 
have fundamentally different origins, with the former losing one or  
 
more suppressor genes on chromosome 9q and the latter having TP53,  
 
RB, and/or P16 abnormalities as early events.  
 
A papilloma (grade 0) is  a papillary lesion with a fine  
 
fibrovascular core covered by normal bladder mucosa ( Friedell et al,   
 
1976 ; Cheng et al,  1999c ) .It does not have more than seven epithelial  
 
cell  layers nor any abnormalities in histology. This is an extremely rare  
 
tumor that,  unlike TCCs, almost never recurs after endoscopic  
 
resection, so that if it occurs alone, it  may legitimately be considered  
 
to be a benign neoplasm (Cheng et al,  1999c ).  However, it  must be  
 
remembered that a histologic papilloma is often found in the same  
 
bladder as higher-grade urothelial cancer, clouding the certainty of its  
 
benignity. Molecular analyses of these lesions have not been reported. 
 
Well-differentiated tumors have a thin fibrovascular stalk with a  
 
thickened urothelium containing more than seven cell layers, with cells  
 
exhibiting only slight anaplasia and pleomorphism. The disturbance of  
 
the base-to-surface cellular maturation is mild, and there are only rare  
 
mitotic figures. When they are mucosally confined, these have been  
 
termed papillary urothelial tumors of low malignant potential by the  
 
WHO and the ISUP (Epstein et al,  1998 ).  However, even when  
 
detected alone, they often recur, and recurrences may be of higher  
 
histologic grade and stage (Cheng et al,  1999c ).  Lesions with this  
 
appearance (similar to those formerly called grade 1) are urothelial  
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cancers. They are found in the same bladders (and frequently in the  
 
same individual tumors) as higher-grade cancers ( Cheng et al,  2000a ),   
 
and share similar molecular ( Cote and Chatterjee,  1999 ) and  
 
prognostic features with low-grade cancers ( Cheng et al,  1999c ;  
 
Cheng and Bostwick, 2000 ; Oyasu, 2000 ). 
 
Moderately differentiated (low grade—old grade 2) tumors have  
 
a wider fibrovascular core, a greater disturbance of the base-to-surface  
 
cellular maturation, and a loss of cell polarity. The nuclear- 
 
cytoplasmic ratio is higher, with more nuclear pleomorphism and  
 
prominent nucleoli.  Mitotic figures are more frequent. These have been  
 
termed low-grade urothelial carcinomas in the new WHO and ISUP  
 
classification (Epstein et al,  1998). Murphy and colleagues (2002)  
 
point out the difficulties for even experienced practitioners to  
 
distinguish between low malignant potential and low-grade carcinoma  
 
lesions as defined in the current classification. 
 
Poorly differentiated tumors, named high-grade urothelial  
 
carcinoma in the new WHO and ISUP system ( Epstein et al,  1998 )  
 
(old grade 3), have cells that do not differentiate as they progress from  
 
the basement membrane to the surface. Marked nuclear pleomorphism  
 
is  noted, with a high nuclear-cytoplasmic ratio. Mitotic figures may be  
 
frequent ( Friedell et al,  1980 ).  The changes made in the new  
 
classification may allow grouping together of a larger number of  
 
patients who are at high risk for progression. 
 
Metaplastic Elements  
 
It  is not unusual for different tumor types to coexist in the same  
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bladder; however, all  epithelial tumors are believed to have a common  
 
ancestry in the transitional epithelium. The presence of these  
 
metaplastic elements (e.g.,  SCC and adenocarcinoma) in a lesion that is   
 
primarily a urothelial carcinoma does not change the principal  
 
classification of the tumor as a urothelial  carcinoma.  
 
Squamous Cell Carcinoma  
 
Etiology  
 
Considerable variability is noted in the prevalence of SCC of the  
 
bladder in different parts of the world. It accounts for only 1% of  
 
bladder cancers in England ( Costello et al,  1984 ), 3% to 7% in the  
 
United States ( Koss, 1975 ; Lynch and Cohen, 1995 ),  but as many as  
 
75% in Egypt ( El-Bolkainy et al,  1981 ).  About 80% of SCCs in Egypt  
 
are associated with chronic infection with S. haematobium. These  
 
cancers occur in patients who are, on the average, 10 to 20 years  
 
younger than patients with TCC. Bilharzial cancers are exophytic,  
 
nodular,  fungating lesions that are usually well differentiated and have  
 
a relatively low incidence of lymph node and distant metastases.  
 
Whether the low incidence of distant metastases is due to capillary and  
 
lymphatic fibrosis resulting from chronic schistosomal infection  
 
(  Ghoneim and Awad, 1980 ) or to the relatively low histologic grade  
 
(  El-Bolkainy et al,  1981 ) of these tumors is not clear.  
 
Nonbilharzial SCCs are usually caused by chronic irritation from  
 
urinary calculi,  long-term indwelling catheters, chronic urinary  
 
infections, or bladder diverticula. As many as 80% of paraplegics with  
 
chronic infections and/or indwelling catheters have squamous changes  
  
31
 
in the bladder, and about 5% develop SCC ( Bahnson, 1997 ).  Cigarette  
 
smoking has also been reported to be significantly associated with an  
 
increased risk of bladder SCC ( Kantor et al,  1988 ).  Male  
 
predominance is far less striking in SCC (1.3:1 to 1.7:1) ( Lynch and  
 
Cohen, 1995 ).  In general,  i ts prognosis is poor because most patients  
 
have advanced disease at the time of diagnosis. 
 
Histology  
 
SCC consists,  characteristically, of keratinized islands that  
 
contain eccentric aggregates of cells called squamous pearls.  They may  
 
show varying degrees of histologic differentiation (Koss, 1975).  
 
Cytology has been of limited utility in the diagnosis of this tumor. In a  
 
small series of patients with SCC, urinary excretion of psoriasin,  
 
produced by the tumor, was found in all cases (Ostergaard et al,  1997).  
 
However, because this protein is also excreted in squamous metaplasia,  
 
it  is unlikely that this test is specific enough to be used in the  
 
diagnosis or screening of SCC or in the monitoring of patients who  
 
have not undergone cystectomy. 
 
Histologic differentiation more loosely correlates with prognosis,  
 
stage for stage, than it  does with urothelial carcinomas, but grade and  
 
node status still predict subsequent metastases ( Zaghloul, 1996 ).   
 
Particularly with bilharzial SCCs, bone is the most common site of  
 
distant metastases ( Zaghloul,  1996 ).  As with aggressive urothelial  
 
cancer, SCCs often have P16 and TP53 abnormalities (Cote and  
 
Chatterjee, 1999 ), although the mechanisms of gene silencing often  
differ between the two tumor types ( Tsutsumi et al,  1998 ). Several  
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reports suggest that,  stage for stage, the prognosis of SCC is  
 
comparable to that of TCC (Johnson et al,1976;Richie et al,  1976 ). 
 
Adenocarcinoma  
 
Adenocarcinomas account for less than 2% of primary bladder  
 
cancers ( Kantor et al,  1988 ; Lynch and Cohen, 1995 ). They are  
 
classified into three groups: (1) primary vesical; (2) urachal; and (3)  
 
metastatic ( Manunta et al,  2005 ).  Adenocarcinomas also occur in  
 
intestinal urinary conduits,  augmentations, pouches, and  
 
ureterosigmoidostomies ( Husmann and Spence, 1990 ; Spencer and  
 
Filmer, 1991 ).   
 
Primary Vesical Adenocarcinoma  
 
Adenocarcinomas usually arise in the bladder base area or in the  
 
dome, but they can occur anywhere. It  is the most common type of  
 
cancer in exstrophic bladders. These tumors develop in response to  
 
chronic inflammation and irritation (Nielsen and Nielsen, 1983 ;  
 
Bennett et al,  1984). 
 
All histologic variants of enteric adenocarcinoma occur in the  
 
bladder. Most are mucin producing (Koss, 1975). Signet-ring  
 
carcinomas characteristically produce linitis plastica of the bladder  
 
(Choi et al,  1984; Sheldon et al,  1984; Blute et al,  1989a). Most  
 
adenocarcinomas are poorly differentiated and invasive. They are more  
 
commonly associated with cystitis glandularis than with carcinoma in  
 
situ. 
The generally poor prognosis associated with adenocarcinomas is  
 
due primarily to their advanced stage at diagnosis. There is no  
 
evidence to indicate that,  stage for stage, their prognosis is  markedly  
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different from that of urothelial carcinoma. 
 
Urachal Carcinoma  
 
Urachal carcinomas are extremely rare tumors that arise outside  
 
the bladder, and they are usually adenocarcinomas, although they may  
 
be primary TCCs or SCCs and, rarely, even sarcomas. Urachal  
 
carcinomas have a sharp demarcation between the tumor and the  
 
adjacent bladder epithelium, with the tumor being located in the  
 
bladder wall beneath the normal epithelium ( Mostofi, 1954 ).  They  
 
may appear with a bloody or mucoid discharge from the umbilicus or  
 
produce a mucocele, occurring as a palpable mass. Many urachal  
 
tumors have stippled calcifications on radiographs ( Brick et al,  1988 ;  
 
Narumi et al,  1988 ). Tumors invading the bladder lumen may produce  
 
mucus in the urine. 
 
Patients with urachal carcinomas have a worse prognosis than do  
 
those with primary bladder adenocarcinomas ( Mostofi,  1954 ).   
 
Histologically, these tumors exhibit wider and deeper infiltration of the  
 
bladder wall than expected, compromising the results of partial  
 
cystectomy ( Kakizoe et al,  1983 ; Sheldon et al,  1984 ). Urachal  
 
carcinomas metastasize to iliac and inguinal lymph nodes, omentum,  
 
liver,  lung, and bone ( Sheldon et al,  1984 ). 
 
Metastatic Adenocarcinoma  
 
One of the most common forms of adenocarcinoma of the bladder  
 
is  metastatic (or invasive) adenocarcinoma ( Choi et al,  1984 ). The  
 
primary sites for these tumors include the rectum, stomach,  
 
endometrium, breast,  prostate, and ovary (Klinger, 1951). 
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MATERIALS AND METHODS 
Study was conducted from November 2007 to January 2010 in our 
department of urology. All patients with haematuria were evaluated and those 
having a bladder tumor included in the study.  Initially few patients with 
tumors more than 6 cm were included in the study, but later tumors less than 5 
cm only were studied. 
Patients were first stabilised and intra venous fluids given , then blood 
sample taken for lab investigations and grouping - typing.The coagulation 
profile also checked. Patients who presented with clot retention were subjected 
to cystoscopic clot evacuation in the daycare cystoscopy room and a 22F 
urethral foley inserted and irrigation started. 
When the patient has stabilized and the haematuria had settled down 
USG KUB was done again and the findings recorded. Cytology was done. 
When the Sr. Creatinine was normal CECT was taken.None of the patients in 
the study had refractory haematuria, haematuria settled down in a maximum of 
2 days. Twelve patients required blood transfusion as their haemoglobin was 
less than 10 gms. None of the patients were in shock at the time of presentation. 
USG was done in our department as we scan routinely for our out and in 
patients. Imaging was done with full bladder in longitudinal and transverse 
sections. The USG achine used is a B Type equipment with a 1.5x zoom.The 
probe can be used in 2.5/3.5/5 MHz mode. It is an electronic convex array 
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probe with a 60mm radius and a 60º scanning angle. The USG findings were 
recorded for data analysis to be done later. 
CECT was done with PHILIPS 64 slice CT .Plain KUB images were 
acquired first then  80 ml of non ionic contrast was administered intra venously 
and CT KUB images were acquired at 30 seconds (Cortico medullary phase) 
and 150 seconds (excretory phase) as 0.625 mm continuous slices  with 1mm 
reconstruction. The Pitch was 1. Then the patient is asked to wait for 30 min 
for bladder imaging. During this period the patient is made ambulant to permit 
the mixing of contrast with urine in the bladder. Screening cystogram is taken 
to make sure that the bladder is filled with contrast and also to check whether 
there is good mixing of the contrast. When a good homogenous cystogram is 
seen bladder imaging is done and images were acquired. 
Virtual endoscopic reconstruction made at the workstation by volume 
rendering algorithm and multiplanar image reconstruction with the Philips 
brilliance extended view 2 software. It took upto 1 hour for reconstruction and 
interpretation. Virtual endoscopic examination of the ureters and pelvis was 
also done in addition to the bladder. There were no associated tumors of the 
pelvis or ureter reported in the patients involved in the study. The image 
interpretation and reporting was done by a single radiology assistant. 
Conventional cystoscopy and tumor resection was done preferentially 
under Spinal anaesthesia. A preliminary cystoscopy was done using a 21F 
sheath and a 30 degree telescope. The site of tumor, relation to ureteric orifice, 
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size, morphology and suspicious areas suggesting CIS were noted. Areas 
appearing as “red velvety” patches were biopsied with Cup Biopsy forceps and 
were sent separately for analysis. Following which using a 24F sheath, a 30 
degree telescope and TURP working element all grossly visible tumor were 
resected as much as possible and specimen stored to be sent seperately. Then 
cold cup biopsy forceps were used to take biopsy at multiple sites in the tumor 
bed for muscle sample and they sent in separate container for HPE. Obturator 
block was used in cases were tumor was involving the lateral wall. 
Haemostasis was secured with loop and/or ball electrode 22F three way 
urethral foley was inserted for irrigation which was removed the next day if 
returns were clear. Mitomycin C 40 mg in 40 ml of saline was given intra 
vesically and held for 1 hour in post op ward in small tumors which were 
completely resected. The procedure was done by a skilled urology assistant and 
the findings were recorded by the person who had operated and were later 
collected for analysis. 
The data were collected in the proforma sheet (model given in appendix) 
for analysis from the USG, Virtual endoscopic and conventional cystoscopic 
reporting.As there were no tumors in the upper tract there is no data for 
analyzing the sensitivity of virtual endoscopy in these context. So data 
collection was pertaining only for virtual cystoscopic evaluation. The following 
data were collected: 
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1.  Site: There are 6 possible sites within the bladder where a tumor can 
arise. They are anterior, posterior, dome, right and left lateral wall, and 
base. 
2.  Size: largest diameter was taken 
3. Morphology: sessile or papillary 
4.  Number of the tumors 
Sensitivity of USG and Virtual cystoscopy in detecting lesions of 
various sizes was determined and compared with Conventional cystoscopic 
findings. 
Also the final Histopathology of the tumor recorded. 
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OBSERVATION AND RESULTS 
Totally 106 patients were evaluated. 
Of these 54 patients were included in the study as they had a bladder 
tumor detected by cystoscopy and/or Ultrasonography and/ or Virtual 
cystoscopy or there were no tumor.Those patients who had no tumor on 
conventional cystoscopic examination comprised the true negative group. 
Those lesions present on cystoscopic examination but absent on USG or 
Virtual cystoscopy are considered to have been missed by the above imaging 
modality and represent the false negative group respectively. Those lesions 
detected on USG and VC but not present on Conventional cystoscopy were 
considered as false positives for the respective imaging study. Of the 54 
patients 38 had a bladder tumor on conventional cystoscopy and 16 didn’t have. 
Two of the bladder tumors were recurrent bladder tumors (patient 17 and 30). 
Of the 16 patients 10 were reported to contain a bladder tumor by USG and/or 
VC, they comprise the false positives. Whereas 6 patients had no lesion 
detected by imaging and by conventional cystoscopy. 
About 10 patients were were excluded from the study as they had raised 
renal parameters. And further 13 patients were excluded as they had large 
bladder growths( > 5 cm ). 
  
39
Patients who were found to have causes other than bladder tumor in the 
study were: 
1. Vesical calculus :3 patients 
2. Renal stone : 10 patients 
3. Ureteric stones : 5 patients 
4. BPH : 13 patients 
5. Carcinoma of prostate : 2 patients 
6. UTI : 9 patients 
7. Renal cell carcinoma : 5 patients 
8. Coagulopathy : 5 patients 
- 3 were on heparin treatment for deep vein thrombosis 
- 1 was on aspirin therapy for Ischemic heart disease 
- 1 was a patient on heparin treatment for post traumatic illiac 
artery thrombosis 
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DESCRIPTIVE STATISTICAL DATA 
 
 
Sex Distribution : 
 
 
Gender Frequency(n) 
Percent 
(%) 
Male 38 70.4 
Female 16 29.6 
Total 54 100.0 
 
 
Of the 54 patients in the study 38 (70.4 %) were males and 16 (29. 6 %) 
females. 
 
AGE DISTRIBUTION 
 
Age group 
Frequency 
(n) 
Percent 
(%) 
Up to 45yrs 2 3.7 
46 - 50yrs 14 25.9 
51 - 55yrs 14 25.9 
56 - 60yrs 16 29.6 
61yrs and above 8 14.9 
Total 54 100.0 
 
Most of the patients were in the age group of 46 to 60 years.  
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GENDER AND AGE DISTRIBUTION 
 
Gender Vs Age group 
Male Female 
n % n % 
Upto 45yrs 2 5.3 0 0.0 
46 - 50yrs 10 26.3 4 25.0 
51 - 55yrs 12 31.6 2 12.5 
56 - 60yrs 8 21.1 8 50.0 
61yrs and above 6 15.8 2 12.5 
Total 38 100.0 16 100.0 
 
In males the most frequent age group is 51 – 55 years where as in 
females it is 56 – 60 years. 
 
Age (yrs) N Minimum Maximum Mean 
Std. 
Deviation 
Male 38 43 72 54.03 6.378 
Female 16 46 63 55.37 5.667 
Total (Both) 54 43 72 54.43 6.154 
 
 
The minimum age is 43 years and the maximum was 72 years. 
 
 
Of the 54 patients 20 patients had microscopic haematuria on evaluation 
and 34 presented with gross haematuria. All the 20 patients with microscopic 
haematuria the main presenting complaint was storage ( irritative ) LUTS. 
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Of the 38 of 54 patients with bladder tumor 51 bladder tumors were 
detected as five of them had multiple bladder tumors. 
Of the 51 bladder tumors only 3 of them were larger than 5 cm as we 
preferred to evaluate lesions less than 6 cm. One of the large bladder tumor was 
the first patient and after which we decided not to evaluate these large tumors 
as there was no use. Other two were special cases, one was a adenocarcinoma 
and other was a mesenchymal tumor of the bladder. 
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SITE DISTRIBUTION OF THE TUMOR 
 
 
 
Site 
Frequency 
(n) 
Percent 
(%) 
Anterior 18 35.3 
Posterior 13 25.5 
Base 4 7.8 
Dome 5 9.8 
L lateral 5 9.8 
R lateral 6 11.8 
Total 51 100.0 
 
Most of the tumors were located in the anterior wall (18 / 51) and the 
posterior wall (13 / 51). 
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MORPHOLOGY DISTRIBUTION 
 
Papillary / Sessile Frequency (n) 
Percent 
(%) 
Papillary 42 82.4 
Sessile 9 17.6 
Total 51 100.0 
 
 
Most of the tumors were papillary (82. 4 %) type, probably as we 
included small sized tumors in the study. 
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DIAGNOSTIC TEST EVALUATION  
 
Ultrasonography Vs Conventional Cystoscopy 
 
 
 
Conventional 
Cystoscopy Total 
Positive Negative 
Ultra 
sonography 
Positive 25 7 32 
Negative 26 9 35 
Total 51 16 67 
 
P.Value = 0.713  (Not significant) 
 
Parameter Estimate 95% CIs Lower - Upper 
Sensitivity 49.02% (35.86,   62.32) 
Specificity 56.25% (33.18,   76.90) 
Positive Predictive Value 78.13% (61.24,   88.98) 
Negative Predictive Value 25.71% (14.16,   42.07) 
Diagnostic Accuracy 50.75% (39.06,   62.35) 
 
 
Ultrasound was found to have an sensitivity of 49.02 % as it detected 25 
/ 51 tumors. All the missed lesions 26/51 were less than 3 cm . Missed lesions 
were located in the anterior wall (15/26 = 57.69 % ) , posterior wall (7/ 26 = 
26.92 % ) and dome ( 4/26 ). Smaller lesions in lateral walls were detected. So 
ultrasound is not a sensitive tool for detecting lesions less than 3 cm in the 
anterior and posterior bladder wall. This is probably due to the reverberation 
artifact. 
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VIRTUAL CYSTOSCOPY VS CONVENTIONAL CYSTOSCOPY 
 
 
 
Conventional 
Cystoscopy Total 
Positive Negative 
Virtual 
Cystoscopy 
Positive 47 3 50 
Negative 4 13 17 
Total 51 16 67 
 
P.Value = <0.001 (Significant) 
 
Parameter Estimate 
95% CIs 
Lower - Upper 
Sensitivity 92.16% (81.50,   96.91) 
Specificity 81.25% (56.99,   93.41) 
Positive Predictive Value 94.00% (83.78,   97.94) 
Negative Predictive Value 76.47% (52.74,   90.45) 
Diagnostic Accuracy 89.55% (79.97,   94.85) 
 
 
Virtual cystoscopy had a sensitivity of 92.16 % as it detected 47 of 51 
tumors.  And further analysis were done for sensitivity of the imaging 
modalities for tumor size less than / equal to 1 cm and more than 1 cm. 
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Size of the lesion is less than or equal to 1 cm (Ultrasound) 
 
 
 
 
Conventional 
Cystoscopy Total 
Positive Negative 
Ultra 
sonography 
Positive 0 7 7 
Negative 21 9 30 
Total 21 16 37 
 
P.Value = 0.003 (Significant) 
 
 
Parameter Estimate 
95% CIs 
Lower - Upper 
Sensitivity 0.0% (0.0,   15.46) 
Specificity 56.25% (33.18,   76.90) 
Positive Predictive Value 0.0% (0.0,   35.43) 
Negative Predictive Value 30.00% (16.66,   47.88) 
Diagnostic Accuracy 24.32% (13.36,   40.12) 
 
Ultrasound was unable to detect tumors less than/equal to 1cm. 
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Size of the lesion is less than or equal to 1 cm (Virtual Cystoscopy ) 
 
 
 Conventional Cystoscopy Total 
Positive Negative 
Virtual 
Cystoscopy 
Positive 17 3 20 
Negative 4 13 17 
Total 21 16 37 
 
 
P.Value = <0.001 (Significant) 
 
Parameter Estimate 95% CIs Lower - Upper 
Sensitivity 80.95% (60.00,  92.33) 
Specificity 81.25% (56.99,  93.41) 
Positive Predictive Value 85.00% (63.96,  94.76) 
Negative Predictive Value 76.47% (52.74,  90.45) 
 
Sensitivity falls down when the size of the lesion is below 1 cm. 
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RESULTS: SIZE OF THE LESION IS MORE THAN 1 CM 
 
 
Ultrasound: 
 
 
 
Conventional 
Cystoscopy 
Total 
Positive Negative 
Ultra 
sonography 
Positive 25 0 25 
Negative 5 0 5 
Total 30 0 30 
 
P.Value = Not possible 
 
 
 
Parameter Estimate 
95% CIs 
Lower - Upper 
Sensitivity 83.33% (66.44,  92.66) 
Specificity --  
Positive Predictive Value 100% (86.68, 100) 
Negative Predictive Value 0.0% (0.0,  43.45) 
Diagnostic Accuracy 83.33% (66.44,  92.66) 
 
 
Sensitivity improves when the size is more than 1cm. (83. 33 %) 
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Virtual Cystoscopy : 
 
 
 
Conventional 
Cystoscopy 
Total 
Positive Negative 
Virtual 
Cystoscopy Positive 30 0 30 
Negative 0 0 0 
Total 30 0 30 
 
P.Value = Not possible 
 
 
Parameter Estimate 95% CIs Lower - Upper 
Sensitivity 100% (88.65,  100) 
Specificity --  
Positive Predictive Value 100% (88.65,  100) 
Negative Predictive Value --  
Diagnostic Accuracy 100% (88.65,  100) 
 
Virtual cystoscopy detects all the tumors above 1 cm in size. 
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Carcinoma in situ was present in 5 patients and Virtual cystoscopy was 
not able to identify it. In these patients 4 had a positive cytology. 
Of the 38 patients who had bladder tumor only 6 patients had a   positive 
cytology with a sensitivity of only 15.78 %. 
TURBx (Trans - urethral resection biopsy) was done in two patients 
where some residual tumor was left unresected. One was a transitional cell 
carcinoma and other adenocarcinoma of the bladder with obvious T3 stage. 
One patient had a partial cystectomy done. The patient presented as a 
mass abdomen and initially thought to arise from the uterus. It was an intra 
mural growth of bladder  and cystoscopy revealed the mucosa to be intact over 
the growth. So a Trans – abdominal trucut biopsy was done and later the 
patient taken for partial cystectomy believing it to be a leiomyoma of bladder. 
Final specimen on immunohistochemical analysis revealed it as a mesenchyal 
tumor. 
Rest of the patients was subjected to TURBT (Trans- urethral resection 
of bladder tumor) where all the grossly visible tumor was resected. Two of the 
resected tumors were found to be benign, chronic cystitic changes. Rests were 
transitional cell carcinoma. 
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DISCUSSION 
Virtual cystoscopy has a high sensitivity, 92.16 % and 100 % sensitivity 
to tumors more than 1 cm. But this is still inferior to conventional cystoscopy. 
Also it misses out carcinoma in situ. This can be overcome by combining 
cytology with it. Although cytology by it self has poor sensitivityfor low grade 
tumor it has high sensitivity for high grade lesions like CIS. Table below sums 
up the results of the study. 
 
 Sensitivity 
Cytology 15.78 % 
USG 49.02 % 
Virtual cystoscopy 92.16 % 
 
 
 
So it appears that virtual cystoscopy is not sensitive enough to replace 
conventional cystoscopy. So we need other modalities for screening for 
urothelial tumors. Lots of work is currently focused on olecular markers.  
Hence in the future we have to rely on molecular markers for avoiding 
unnecessary cystoscopy in those patients who don’t have a urothelial tumor. 
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Role of molecular was emphasized by Bryan et al , Goodison et al and 
Ehdaie et al “Molecular markers will become increasingly important for 
urothelial cancer diagnosis and prognostication as we continue through the 
century, with both conventional and novel experimental platforms providing 
robust and reproducible assays with high sensitivity and specificity, and point-
of-care utility. 
(Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. 
Biomarkers in bladder cancer. BJU Int 2010; 105 : 608– 1311. 
Goodison S, Rosser CJ, Urquidi V. Urinary proteomic profiling for 
diagnostic bladder cancer biomarkers.Expert Rev Proteomics 2009; 6 : 507–14. 
Ehdaie B, Theodorescu D. Predicting tumor outcomes in urothelial 
bladder carcinoma: turning pathways into clinical biomarkers of prognosis. 
Expert Rev Anticancer Ther 2008;8 : 1103–10 ). 
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I close this discussion with the quote “Finally, we think that cystoscopy 
will remain the ‘gold standard’ for ruling out bladder cancer in the haematuria 
patient as of now. However, conventional white light cystoscopy will evolve to 
embrace new imaging technologies with improved capabilities, such as narrow 
band and optical coherence tomography.” 
-Richard T. Bryan and Michael A. Wallace, 
Bladder Cancer Prognosis Programme Bladder 
Cancer Prognosis Programme, 
University of Birmingham, UK 
Cystoscopy is easy to teach, familiar to all urologists, reasonably 
accurate and performed with low morbidity around the world. It is performed 
in minutes, in contrast to virtual cystoscopy, which takes time. 
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CONCLUSION 
 
Despite the obvious benefits of virtual cystoscopy in terms of less 
invasiveness and more comfort to the patient, it has several limitations. These 
include, 
 
1. Low detection rate for lesions smaller than 1 cm 
2. Not able to detect CIS. 
3. Inferior to conventional cystoscopy in detecting bladder lesions. 
 
So Virtual cystoscopy cannot replase conventional cystoscopy. It may 
have a place in the evaluation of patients with haematuria in stricture disease 
and surgically poor risk patients. 
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GLOSSARY 
USG : Ultrasound/Ultrasonogram 
KUB :  Kidney, Ureter and Bladder 
VE :  Virtual endoscopy 
VC :  Virtual cystoscopy 
CECT :  Contrast enhanced CT 
CT :  Computerised tomogram 
CIS :  Carcinoma in Situ 
LUTS :  Lower urinary tract symptoms 
1  :  Positive (+) 
0  :  Negative (-) 
TURBT     : Transurethral resection of bladder tumor 
TURBx     : Transurethral resection biopsy 
TCC : Transitional cell carcinoma  
Ch CYS : Chronic cystitis 
Adeno CA : Adenocarcinoma 
Mesen T  : Mesenchymal tumor 
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AGE:  SEX: 
 
 
 
ADDRESS: 
 
 
 
 
 
CONTACT NUMBER: 
 
 
IP NO:       OP NO: 
 
 
 
PRESENTING COMPLAINTS: 
 
 
 
 
 
 
 
 
 
 
 
 
PHYSICAL EXAMINATION: 
 
 
 
 
 
 
 
 
 
INVESTIGATION: 
 
 
1.URINE: 
 
ALBUMIN 
 
SUGAR 
 
DEPOSITS 
 
 
2.URINE CULTURE AND SENSITIVITY: 
 
 
 
3.HAEMOGRAM: 
 
HB 
TC 
DC 
ESR 
 
4.URINE CYTOLOGY: 
 
 
 
 
5.USG KUB: 
 
(R) KIDNEY: 
 
 
 
 
 
(L) KIDNEY: 
 
 
 
 
 
  
BLADDER: 
 
Number of Lesion   site   size 
 morphology      
 
 
 
 
 
 
 
 
 
 
 
 
6.VIRTUAL ENDOSCOPY FINDINGS: 
 
 
Number of Lesion   site   size 
 morphology    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. CONVENTIONAL ENDOSCOPY FINDINGS: 
 
 
Number of Lesion   site   size 
 morphology    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.HISTOPATHOLOGY REPORT : 
 
 
 
 
 
 
 
 
 
 
 
9.COMMENTS: 
 
 
 
  
  
 
CONSENT FORM 
 
 I have clearly understood the need for the investigation VIRTUAL 
ENDOSCOPY from the doctor. I also understand that this investigation is 
being done for the evaluation of blood in the urine. I was also explained that a 
CT scan will be taken, which need exposure to X- rays and an intra- venous 
contrast agent will be injected. I was also explained the side effects of the X- 
rays and the contrast agent. Having fully understood the implications I consent 
for the above investigation whole heartedly 
 
 
 
                                                                               (Signature of the Patient) 
 
patient age sex Haematuria leison site size (cm) papillary/sessile USG +/ - VC + / - Cytology +/- CIS Surgery HPE
1 45 M gross 1 R lateral 6 sessile 1 1 1 0 TURBx TCC
2 Dome 1 papillary 0 1 TURBT TCC
3 anterior 0.5 papillary 0 1 TURBT TCC
4 anterior 0.5 papillary 0 1 TURBT TCC
2 50 M gross 1 posterior 4 papillary 1 1 0 0 TURBT TCC
3 47 M gross 1 anterior 5 sessile 1 1 0 0 TURBT TCC
4 60 M gross 1 l lateral 4 papillary 1 1 0 0 TURBT TCC
5 54 M gross 1 l lateral 3.5 papillary 1 1 0 0 TURBT TCC
6 65 M microscopic 1 Dome 2.5 papillary 0 1 0 0 TURBT TCC
7 46 M gross 1 anterior 1 papillary 0 1 0 0 TURBT TCC
8 47 F gross 1 R lateral 4 sessile 1 1 0 0 TURBT TCC
9 51 M gross 1 anterior 5 sessile 1 1 0 0 TURBT TCC
10 53 M gross 1 l lateral 4 sessile 1 1 1 1 TURBT TCC
2 anterior 1 papillary 0 1 TURBT TCC
3 anterior 0.5 papillary 0 0 TURBT TCC
4 anterior 0.5 papillary 0 1 TURBT TCC
5 anterior 0.4 papillary 0 0 TURBT Ch. CYS
11 58 M gross 1 R lateral 4 sessile 1 1 1 1 TURBT TCC
12 61 M gross 1 R lateral 6 sessile 1 1 0 0 TURBx Adeno CA
13 59 F gross 1 posterior 2.5 papillary 1 1 1 1 TURBT TCC
2 posterior 1 papillary 0 1 TURBT TCC
3 posterior 0.5 papillary 0 1 TURBT TCC
4 posterior 0.5 papillary 0 1 TURBT TCC
14 54 M 1 l lateral 2.8 papillary 1 1 0 0 TURBT TCC
15 51 M microscopic 1 posterior 1 papillary 0 1 0 0 TURBT TCC
16 47 M microscopic 1 anterior 1 papillary 0 1 0 0 TURBT TCC
17 46 F gross 1 posterior 3.5 papillary 1 1 0 0 TURBT TCC
18 56 M gross 1 anterior 1 papillary 0 1 0 0 TURBT TCC
19 55 M gross 1 Base 2.5 papillary 1 1 0 0 TURBT TCC
20 61 F gross 1 Dome 1 papillary 0 1 0 0 TURBT TCC
21 63 M gross 1 posterior 2.5 papillary 1 1 0 0 TURBT TCC
22 46 M gross 1 posterior 4.5 sessile 1 1 1 1 TURBT TCC
2 anterior 1 papillary 0 1 TURBT TCC
patient age sex Haematuria leison site size (cm) papillary/sessile USG +/ - VC + / - Cytology +/- CIS Surgery HPE
3 anterior 0.5 papillary 0 0 TURBT TCC
23 51 M gross 1 anterior 1 papillary 0 1 0 0 TURBT TCC
24 60 F gross 1 Base 2.5 papillary 1 1 0 0 TURBT TCC
25 55 M gross 1 Base 1.8 papillary 1 1 0 0 TURBT TCC
26 72 M gross 1 Base 2.2 papillary 1 1 0 0 TURBT TCC
27 47 F microscopic 1 Dome 8 sessile 1 1 0 0 Par. Cys Mesen. T
28 49 M gross 1 R Lateral 1.8 papillary 1 1 0 0 TURBT TCC
29 58 M gross 1 Posterior 1.5 papillary 0 1 0 0 TURBT TCC
30 59 F gross 1 Dome 1.7 papillary 0 1 0 0 TURBT TCC
31 65 M gross 1 Anterior 1.6 papillary 0 1 0 0 TURBT TCC
32 47 F gross 1 Anterior 1.5 papillary 0 1 0 0 TURBT TCC
33 49 M gross 1 Posterior 2.5 papillary 1 1 0 0 TURBT TCC
gross 2 Anterior 0.5 papillary 0 0 TURBT Chr. CYS
34 53 M microscopic 1 Anterior 1.8 papillary 1 1 0 1 TURBT TCC
35 51 M microscopic 1 Posterior 1 papillary 0 1 0 0 TURBT TCC
36 60 M gross 1 R Lateral 1.6 papillary 1 1 0 0 TURBT TCC
37 59 F gross 1 L Lateral 2.7 papillary 1 1 1 0 TURBT TCC
38 58 F microscopic 1 Posterior 1 papillary 0 1 0 0 TURBT TCC
39 56 M microscopic 0 NA NA NA 1 0 0 0 NA NA
40 54 F microscopic 0 NA NA NA 0 0 0 0 NA
41 57 F gross 0 NA NA NA 0 0 0 0 NA
42 60 M microscopic 0 NA NA NA 1 0 0 0 NA
43 49 M microscopic 0 NA NA NA 0 1 0 0 NA
44 52 M microscopic 0 NA NA NA 1 0 0 0 NA
45 47 F gross 0 NA NA NA 0 0 0 0 NA
46 56 M microscopic 0 NA NA NA 1 0 0 0 NA
47 52 M microscopic 0 NA NA NA 0 0 0 0 NA
48 59 F microscopic 0 NA NA NA 0 0 0 0 NA
49 61 M microscopic 0 NA NA NA 1 0 0 0 NA
50 63 F microscopic 0 NA NA NA 1 0 0 0 NA
51 49 M microscopic 0 NA NA NA 0 1 0 0 NA
52 43 M microscopic 0 NA NA NA 0 1 0 0 NA
53 50 M microscopic 0 NA NA NA 0 0 0 0 NA
patient age sex Haematuria leison site size (cm) papillary/sessile USG +/ - VC + / - Cytology +/- CIS Surgery HPE
54 57 F microscopic 0 NA NA NA 1 0 0 0 NA
